3 Spam-Free Article(s) Found
Sort:
Date
Filter:
7d
Article Searches
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More https://www.zacks.com/stock/news/2240974/biotech-stock-roundup-amlx-acad-down-on-study-data-mrna-rgls-gain-on-updates-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2240974 Mar 14, 2024 - Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502 Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study https://www.zacks.com/stock/news/2239307/aslan-asln-up-161-on-upbeat-initial-data-from-eczema-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239307 Mar 12, 2024 - ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.

Pages: 1

Page 1